Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USTiGA: upadacitinib with short glucocorticoid tapering in giant cell arteritis
2025-523199-22-00Phase 3Authorised
- Sponsor
- University of Bonn
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Upadacitinib plus prednisolone taper with Placebo plus prednisolone taper (2 arms). Primary endpoint: Sustained remission from week 12 through week 52. Planned start Oct 2026; status: authorised.
02
Drugs
upadacitinibprednisolone
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2025-523199-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523199-22-00.